Blog: UK’s MHRA Publishes Extensive Post-Transition Brexit Guidance – Lexology

On September 1, 2020, the UK’s medicines and medical devices regulator released the MHRA post-transition information, an extensive suite of guidance on the UK regulatory regime post the Transition Period expiring on December 31, 2020.

The new guidance spreads out across dozens of documents covering the following topics:

  • Clinical trials
  • Devices
  • Licensing
  • Importing and Exporting
  • IT systems
  • Pharmacovigilance
  • Paediatrics

Given that up to now, the industry has been left with no clarity other than the withdrawn previous No-Deal guidance, this publication is largely to be welcomed. It provides more certainty on a number of areas and although it is largely similar to the previous guidance that was withdrawn earlier in 2020, it provides additional detail and in some cases deviates from that guidance, and so requires careful reading.

Extensive though the new guidance is, certain gaps in detail provided still remain, and we continue to follow up with the MHRA in these important areas.

We have prepared a summary of the new guidance, which can be accessed here.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s